This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Simple test for flu could improve diagnosis and surveillance By Allessandra DiCorato June 18, 2024 Breadcrumb Home Simple test for flu could improve diagnosis and surveillance A low-cost CRISPR-based paper strip test distinguishes between influenza types and can be reprogrammed to recognize different viruses including the H5N1 bird flu virus.
William Studier for development of widely used protein- and RNA-production platform By Corie Lok May 14, 2024 Breadcrumb Home Merkin Prize in Biomedical Technology awarded to F. Merkin Prize in Biomedical Technology for his development of an efficient, scalable method of producing RNA and proteins in the laboratory.
When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use. These drugs would be ideal tools to bridge the wait for a vaccine against a quickly-spreading virus.
A Novel Virus Appears In retrospect, everything unfolded with astonishing speed. A few days after New Years, 2020, I heard BBC News report the first cases, in China. Whenever and wherever the virus emerged, CDC officially alerted clinicians to the new, deadly respiratory illness on January 8, 2020.
Monthly News Roundup – December 2020. The messenger RNA (mRNA) vaccines encode a form of the spike (S) protein of SARS-CoV-2 virus. The vaccine teaches the cells to make a piece of the spike protein, which triggers an immune response to help prevent illness if later exposed to the virus.
Posted: December 2020.
We know now that the viral RNA is found in stool and infectious virus as well. Therefore, Carlson said, “we advised no use of fecal donations from after Dec. 1, 2019, until effective screening methods are implemented.”. There were no methods for testing for COVID in stool,” he said. “We Infection in the GI tract is likely.”
He has also emerged in recent years as a skilled and relatable science communicator, renowned for his efforts at Broad and beyond during the COVID-19 pandemic to unpack the fast-moving research on the new virus in an accessible way and give practical advice about masking, vaccines, and other public health measures.
23, 2020 — In a Society for Healthcare Epidemiology of America white paper, published online Oct. The authors recommended viral load thresholds of 1,000 IU for hepatitis B virus (HBV), hepatitis C virus (HCV) RNA undetectable for HCV, and suppressed viral RNA for HIV for determining any restrictions on HCP practice.
LUXEMBOURG–( BUSINESS WIRE )– Eurofins GeneScan Technologies (Paris:ERF) announces that the VIR Seek SARS-CoV-2 Solution has been evaluated and approved by the AOAC Performance Tested Methods SM (PTM) Program on December 29, 2020 and awarded Emergency Response Validation PTM certification number 122006.
Some scientists even think it had a virus defense system; “researchers say LUCA likely housed 19 CRISPR genes, which bacteria use to slice up viral threats,” reports Quanta Magazine. DNA and RNA molecules are also built from exclusively right-handed nucleic acids.
The virus SARS-CoV-2 emerged in Wuhan, home of a premiere research institute that focuses on viruses. An altered virus could have escaped. Evidence that the virus emerged, or escaped, from the wildlife trade is lacking. Her points: 1. Coincidence? I’ve never thought so. RaTG13 shares about 96.1%
22, 2020 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. , The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., BOSTON, Oct. Chief Executive Officer and Founder of Atea Pharmaceuticals.
When doctors sequenced the DNA and RNA found in Alice’s blood and synovial fluid—the liquid that surrounds and lubricates joints—they found abnormally low levels of genes encoding iron-storing proteins and high levels of epidermal growth factor receptor RNA.
Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday. 18, 2020 ). It has also received temporary or conditional authorization in the UK and in the EU ( DID , Jan.
During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.
4, 2020 08:00 UTC. A global Phase 2/3 efficacy study of the S-Trimer vaccine candidate in combination with GSK’s pandemic adjuvant system is expected to begin in December 2020. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. CHENGDU, China.–(
The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.
Because mRNA is not a virus, it doesn’t have to meet biosafety requirements for manufacturing and administration that an AAV approach would need. Additionally, the COVID-19 RNA vaccines have already demonstrated how safe RNA can be, and we look forward to seeing additional safety data on RNA approaches as the field continues to grow.
22, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19.
18, 2020 – The first rapid coronavirus test that can be taken at home with results delivered in 30 minutes was cleared for emergency use by the U.S. Lab tests that look for the coronavirus’s genetic material using a technique called polymerase chain reaction (PCR) are still considered the gold standard for detecting the virus.
Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. 50 c/mL, meeting noninferiority criteria.
Biogazelle, an innovative bioanalytical services company offering RNA and. In April 2020, Biogazelle introduced a high-throughput, modular and scalable SARS-CoV-2 RT-qPCR. Ghent University Hospital for SARS-CoV-2 virus screening. Bioinformatics in the Faculty. of Medicine and Health Sciences (Ghent University) and. therapeutics.
Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza.
For security reasons, at the time COVID-19 had to be grown in BSL-3 labs, which can be dangerous because they were handling the live virus. These are synthetic, not the live virus, so do not pose a risk of infection. Researchers were able to use our synthetic RNA controls as a reference to verify and validate assays.
Basel, 1 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Among them, more than 160,000 people did not know their HIV status, and only 53 percent were virally suppressed having low amounts of virus circulating in their blood. Reviewed June 8, 2020. Accessed July, 24 2020. J Clin Virol.
11, 2020 02:48 UTC. In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.
Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission has granted a conditional marketing authorization (CMA) for COVID-19 Vaccine Moderna, allowing vaccination programs using the Moderna vaccine to be rolled out across the European Union. About Moderna.
Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. The information contained in this release is as of September 9, 2020.
14, 2020 ). 2 virus and the variant first identified in South Africa. Sanofi has also entered into vaccine manufacturing partnerships to help produce the Pfizer/BioNTech, Moderna and Johnson & Johnson shots ( DID , April 13 ), and it is developing a messenger RNA-based vaccine candidate with Translate Bio.
Coronaviruses are RNA viruses and include common human coronaviruses, severe acute respiratory syndrome-CoV (SARS-CoV), Middle East respiratory syndrome-CoV (MERS-CoV) and SARS-CoV-2 ( 1 ). Detection of virus-specific antibodies allows for diagnosis of recent symptomatic or even asymptomatic infections. INTRODUCTION.
Analysis of transcriptional changes using RNA sequencing further confirmed that TT125-802 suppresses key non-oncogene resistance mechanisms including transcriptional networks around stemness, epithelial-mesenchymal transition (EMT), and transforming growth factor beta (TGFβ) signalling. British Journal of Cancer [Internet].
Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. “We remain focused on being proactive as the virus evolves by leveraging the flexibility of our mRNA platform to stay ahead of emerging variants.” On December 18, 2020, the U.S. Moderna, Inc.,
Basel, 1 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will launch a SARS-CoV-2 Rapid Antigen Test, in late September, for markets accepting the CE Mark. This can help healthcare professionals identify a SARS-CoV-2 infection in people suspected to carry the virus with results typically ready in 15 minutes.
The drug companies had hoped to have regulatory approval for their jab in the first half of this year, but interim results from a Phase 1/2 study, released in December 2020, had shown an “insufficient” ? response in the over-50s, the age group deemed at higher risk for contracting the severe form of the virus. .
21 October 2020 — ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. These findings were presented today at the 2020 Infectious Diseases Society of America (IDSA) IDWeek. Kimberly Smith, M.D., About ViiV Healthcare.
for the same period in 2020. This was primarily driven by the impact of higher in-process research and development (“IPR&D”) expenses in the second quarter 2020 related to the Forty Seven, Inc. billion as of December 31, 2020. billion compared to the same period in 2020. Second Quarter 2021 Financial Results.
20, 2020 /PRNewswire/ — Caris Life Sciences® , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Winship Cancer Institute of Emory University (Winship) has joined Caris’ Precision Oncology Alliance (The Alliance/POA). IRVING, Texas and ATLANTA , Oct.
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.
As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.
20, 2020 02:44 UTC. Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. Healthcare workers have been on the front lines of the fight against the virus and are an inspiration to us all. government by the end of December 2020. CAMBRIDGE, Mass.–(
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content